Modern conception of the pathogenesis of neurodegenerative diseases and therapeutic strategy

Litvinenko I.V.; Krasakov I.V.; Bisaga G.N.; Skulyabin I.D.; Poltavsky I.D.

doi:https://doi.org/10.17116/jnevro2017117623-10

Close metadata

Recommended articles:

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30

The experience of diagnosing Alzheimer’s disease based on the study of cerebrospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

Epidemiology of multiple sclerosis in the city of Novosibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127

Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59

The level of hypoxia-induced factor-1a and associated molecules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10

Infectious factors in atopic dermatitis, pharmaceutical possibilities (systematic literature review). Russian Journal of Clinical Dermatology and Venereology. 2025;(1):7-15

A modern perspective on the pathogenesis of proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(1):92-98

Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12

Abstract:

Here we discuss the pathogenesis of the inflammatory and degenerative nervous system disorders on the example of Parkinson’s disease, Alzheimer’s disease, multiple sclerosis. Common mechanisms of neurodegeneration in these diseases are reviewed. The role of neurodegeneration as the main process leading to the resistant disability of patients with multiple sclerosis is discussed. The authors consider a contribution of inflammatory process and chronic infection to the manifestation and progressing of a neurodegenerative disease and discuss the use of treatment not usually indicated including interferon, anti-inflammatory drugs, statin, vitamin D, monoclonal antibodies, correction of the intestinal microbiota in Parkinson’s disease and Alzheimer’s disease.

Keywords:

Parkinson’s disease

Alzheimer’s disease

multiple sclerosis

pathogenesis

inflammation

neurodegeneration

therapy

Authors:

Litvinenko I.V.

Kafedra nervnykh bolezneĭ i kafedra psikhiatrii Voenno-meditsinskoĭ akademii

SPIN RSCI: 6112-2792
Scopus AuthorID: 35734354000
ResearcherID: F-9120-2013
ORCID: 0000-0001-8988-3011

Krasakov I.V.

Bisaga G.N.

Voenno-meditsinskaia akademiia im. S.M. Kirova, klinika nervnykh bolezneĭ, Sankt-Peterburg;
Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza

ORCID: 0000-0002-1848-8775

Skulyabin I.D.

Military Medical Academy, St. Petersburg

Poltavsky I.D.

Kirov Military Medical Academy, St. Petersburg, Russia

Close metadata

References:

Lobzin VYu, Emelin AYu, Odinak MM, Alekseeva LA, Monakhova NE. Value of determining the cerebrospinal fluid protein markers of amyloidosis and neurodegeneration in the diagnosis of vascular and neurodegenerative cognitive impairments. Neurology, neuropsychiatry, Psychosomatics. 2013; 4:21. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2450
Lobzin VYu, Litvinenko IV, Emelin AYu. Hyperhomocysteinemia — vascular damage, neurodegeneration and cognitive impairment progression risk factor. Vestnik Rossiiskoi Voenno-meditsinskoi akademii. 2015;52(4):100-105. (In Russ.).
Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H, Knopman DS, Launer LJ, Saczynski JS, Seshadri S, Zeki Al Hazzouri A; American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):67-94. https://doi.org/10.1161/hyp.0000000000000053
Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Letters. 2011;585(23):3715-3723. https://doi.org/10.1016/j.febslet.2011.08.004
Wang H, Wang K, Xu W, Wang C, Qiu W, Zhong X, Dai Y, Wu A, Hu X. Cerebrospinal fluid α-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. Journal of Neurochemistry. 2012;122(1):19-23. https://doi.org/10.1111/j.1471-4159.2012.07749.x
Gray E, Rice C, Nightingale H, Ginty M, Hares K, Kemp K, Cohen N, Love S, Scolding N, Wilkins A. Accumulation of cortical hyperphosphorylated neurofilaments as a marker of neurodegeneration in multiple sclerosis. Multiple Sclerosis Journal. 2013;19(2):153-161. https://doi.org/10.1177/1352458512451661
Bisaga GN. Multiple sclerosis — neurodegenerative disease Vestnik Rossiiskoi Voenno-meditsinskoi akademii. 2013;44(4)(suppl 2):49-54. (In Russ.).
Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, Cummins GA, Duncan GW, Khoo TK, Burn DJ, Barker RA; ICICLE-PD study group. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Movement Disorders. 2016;31(7):995-1003. https://doi.org/10.1002/mds.26563
Umemura A, Oeda T, Yamamoto K, Tomita S, Kohsaka M, Park K, Sugiyama H, Sawada H. Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease. PLoS One. 2015;10(8):0136722. https://doi.org/10.1371/journal.pone.0136722
Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends in Molecular Medicine. 2014;20(3):179-187. https://doi.org/10.1016/j.molmed.2013.11.007
Bisaga GN, Gaikova ON, Onishchenko LS, Chikurov AA, Pozdniakov AV. Multiple sclerosis: from morphology to pathogenesis. SPb:. B.I.; 2015. (In Russ.).
Mangiardi M, Crawford DK, Xia X, Du S, Simon-Freeman R, Voskuhl RR, Tiwari-Woodruff SK. An animal model of cortical and callosal pathology in multiple sclerosis. Brain Pathology. 2011;21(3):263-278. https://doi.org/10.1111/j.1750-3639.2010.00444.x
Pietroboni AM, Schiano di Cola F, Scarioni M, Fenoglio C, Spanò B, Arighi A, Cioffi SM, Oldoni E, De Riz MA, Basilico P, Calvi A, Fumagalli GG, Triulzi F, Galimberti D, Bozzali M, Scarpini E. CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis. Multiple Sclerosis Journal. 2016. https://doi.org/https://doi.org/ 10.1177/1352458516674566
Furlan R, Brambilla E, Sanvito F, Roccatagliata L, Olivieri S, Bergami A, Pluchino S, Uccelli A, Comi G, Martino G. Vaccination with amyloid-β peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain. 2003;126(2):285-291. https://doi.org/10.1093/brain/awg031
Grant JL, Ghosn EE, Axtell RC, Herges K, Kuipers HF, Woodling NS, Andreasson K, Herzenberg LA, Herzenberg LA, Steinman L. Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of Amyloid-β in Th1- and Th17-Versions of Experimental Autoimmune Encephalomyelitis. Science Translational Medicine. 2012;4(145):145ra105. https://doi.org/10.1126/scitranslmed.3004145
Goodman AD, Gyang T, Smith AD. 3rd.Ibudilast for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs. 2016;25(10):1231-1237. https://doi.org/10.1080/13543784.2016.1221924
Mellergard J, Tisell A, Blystad I, Grönqvist A, Blennow K, Olsson B, Dahle C, Vrethem M, Lundberg P, Ernerudh J. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. European Journal of Neurology. 2017;24(1):112-121. https://doi.org/10.1111/ene.13162
Segura-Ulate I, Yang B, Vargas-Medrano J, Perez RG. FTY720 (Fingolimod) reverses α-synuclein-Induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells. Neuropharmacology. 2017;0028-3908(17)30029-1. https://doi.org/10.1016/j.neuropharm.2017.01.028
Mostafa A, Jalilvand S, Shoja Z, Nejati A, Shahmahmoodi S, Sahraian MA, Marashi SM. Multiple sclerosis-associated retrovirus, Epstein-barr virus, and vitamin D status in patients with relapsing remitting multiple sclerosis. Journal of Medical Virology. 2017. https://doi.org/10.1002/jmv.24774
Spain RI, Powers K, Murchison C, Heriza E, Horak FB, Simon J, Bourdette DN. Lipoic acid for neuroprotection in secondary progressive multiple sclerosis: results of a randomised placebo-controlled pilot trial ECTRIMS Online Library. Sep 16, 2016; 147064. Accessed February 12, 2017. Available at: https://www.mediasphera.ru/journal/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova?expanded=true&tab=authors
Becker J, Callegaro D, Lana-Peixoto MA, Talim N, Vidaletti T, de Paula Corrêa M, Gomes I. Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil. Journal of the Neurological Sciences. 2016;363:236-239. https://doi.org/10.1016/j.jns.2016.02.064
Laursen JH, Sondergaard HB, Sorensen PS, Sellebjerg F, Oturai AB. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders. 2016;10:169-173. https://doi.org/10.1016/j.msard.2016.10.005
Wright CB, Gardener H, Dong C, Yoshita M, De Carli C, Sacco RL, Stern Y, Elkind MS. Infectious Burden and Cognitive Decline in the Northern Manhattan Study. Journal of the American Geriatrics Society. 2015;63(8): 1540-1545. https://doi.org/10.1111/jgs.13557
Illarioshkin SN. Modern view on etiology of Parkinson’s disease. Nevrologicheskiy zhurnal. 2015;20(4):4-13. (In Russ.). https://doi.org/10.18821/1560-9545-2015-20-4-4-13
Litvinenko IV, Odinak MM, Sologub OS, Mogilnaya VI, Schmeleva VM, Saharovskaya AA. Hyperhomocysteinemia in Parkinson’s disease — new variant of complications of ongoing therapy or specific biochemical marker of the disease? Annaly klinicheskoi i eksperimental’noi nevrologii. 2008;2(2):13-17. (In Russ.).
Trufanov AG, Litvinenko IV, Efimtsev AYu. The anatomical brain pathways affection in advanced 2-3 stages (Hoehn, Yahr scale) of Parkinson disease. Vestnik Rossiiskoi Voenno-meditsinskoi akademii. 2012;50(4):36-40. (In Russ.).
Moore AH, Bigbee MJ, Boynton GE, Wakeham CM, Rosenheim HM, Staral CJ, Morrissey JL, Hund AK. Non-Steroidal Anti-Inflammatory Drugs in Alzheimer’s Disease and Parkinson’s Disease: Reconsidering the Role of Neuroinflammation. Pharmaceuticals (Basel). 2010;3(6):1812-1841. https://doi.org/10.3390/ph3061812
Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH, Ritz B. Non-steroidal anti-inflammatory drug use and the risk of Parkinson’s disease. Neuroepidemiology. 2011;36(3):155-161. https://doi.org/10.1159/000325653
Barnum CJ, Chen X, Chung J, Chang J, Williams M, Grigoryan N, Tesi RJ, Tansey MG. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro 1595attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. Journal of Parkinson’s Disease. 2014;4(3):349-360. https://doi.org/10.3233/JPD-40410
Mulas G, Espa E, Fenu S, Spiga S, Cossu G, Pillai E, Carboni E, Simbula G, Jadžić D, Angius F, Spolitu S, Batetta B, Lecca D, Giuffrida A, Carta AR. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson’s disease. Experimental Neurology. 2016;286:83-92. https://doi.org/10.1016/j.expneurol.2016.09.013
Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell. 2016;167(6): 1469-1480.e12. https://doi.org/10.1016/j.cell.2016.11.018
Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sorensen HT. Vagotomy and subsequent risk of Parkinson’s disease. Annals of Neurology. 2015;78(4):522-529. https://doi.org/10.1002/ana.24448
Barrenschee M, Zorenkov D, Böttner M, Lange C, Cossais F, Scharf AB, Deuschl G, Schneider SA, Ellrichmann M, Fritscher-Ravens A, Wedel T. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson‘s disease. Acta Neuropathologica Communications. 2017;5(1):1. https://doi.org/10.1186/s40478-016-0408-2
Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BioMed Central. 2007;5:20. https://doi.org/10.1186/1741-7015-5-20
Gottlieb K, Wacher V, Sliman J, Pimentel M. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Alimentary Pharmacology & Therapeutics. 2016;43(2):197-212. https://doi.org/10.1111/apt.13469
Friedman B, Lahad A, Dresner Y, Vinker S. Long-term statin use and the risk of Parkinson’s disease. American Journal of Managed Care. 2013; 19(8):626-632.
Fuseya Y, Takahashi R. Interferon-β may ameliorate synucleinopathy. Movement Disorders. 2016;31(4):497. https://doi.org/10.1002/mds
Yakhno NN, Nodel MR, Fedorova NV, Artemiev DV, Levin OS, Preobrazhenskaya IS, Smolentseva IG, Obukhova AV, Koberskaya NN, Strutsenko AA. Efficacy and tolerance of pramipexol (mirapex) in long-term therapy of patients with Parkinson’s disease. Nevrologicheskiy zhurnal. 2004;9(3):25-30. (In Russ.).
Levin OS, Fedorova NV, Smolentseva IG. Dopamine agonist in treatment Parkinson’s disease. RMZh. 2000;8(15-16):42-51. (In Russ.).
Lieberknecht V, Junqueira SC, Cunha MP, Barbosa TA, de Souza LF, Coelho IS, Santos AR, Rodrigues AL, Dafré AL, Dutra RC, Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice Molecular Neurobiology. 2016. https://doi.org/10.1007/s12035-016-9717-5
Wang L, Evatt ML, Maldonado LG, Perry WR, Ritchie JC, Beecham GW, Martin ER, Haines JL, Pericak-Vance MA, Vance JM, Scott WK. Vitamin D from different sources is inversely associated with Parkinson disease. Movement Disorders. 2015;30(4):560-566. https://doi.org/10.1002/mds.26117
Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M. α-Synuclein expression is modulated at the translational level by iron. NeuroReport. 2012;23(9):576-580. https://doi.org/10.1097/WNR.0b013e328354a1f0
Lingor P, Carboni E, Koch JC. Alpha-synuclein and iron: two keys unlocking Parkinson’s disease. Journal of Neural Transmission. 2017. https://doi.org/10.1007/s00702-017-1695-x
Goroshko OA. Kukes VG, Prokofiev AB, Arkhipov VV, Demchenkova EY. Clinico-pharmacological aspects of application of antioxidant drugs. International Journal Of Applied And Fundamental Research. 2016;4:905-912. (In Russ.).
Litvinenko IV, Krasakov IV. The therapeutic potential of melatonin in Parkinson’s disease: from normalization of circadian rhythms to neuroprotection. Nevrologiya i revmatologiya. 2012;1:15-18. (In Russ.).
Tsujii S, Ishisaka M, Hara H. Modulation of endoplasmic reticulum stress in Parkinson’s disease. European Journal of Pharmacology. 2015;765:154-156. https://doi.org/10.1016/j.ejphar.2015.08.033
Illarioshkin S.N. The conformational diseases of the brain. M.: Yanus-K; 2003. (In Russ.).
Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, Johnson KA, Growdon JH. Brain amyloid and cognition in Lewy body diseases. Movement Disorders. 2012;27(8):965-973. https://doi.org/10.1002/mds.25048
Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller ML, Albin RL, Frey KA. Amyloid deposition in Parkinson’s disease and cognitive impairment: a systematic review. Movement Disorders. 2015;30(7):928-935. https://doi.org/10.1002/mds.26191
Kotagal V, Bohnen NI, Müller ML, Frey KA, Albin RL. Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease. Journal of Parkinson’s Disease. 2017. https://doi.org/10.3233/JPD-160985
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50-56. https://doi.org/10.1038/nature19323
Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathologica Communications. 2017;5(1):7. https://doi.org/10.1186/s40478-016-0410-8.
Pukhov RV, Bisaga GN, Trufanov AG, Efimtsev AIu, Fokin VA. Brain metabolism in multiple sclerosis: effects of neurotrophic therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113(10):97-104. (In Russ.).